RARA and acute promyelocytic leukemia: However, our frequency data should be carefully interpreted due to several reasons: (1) although the PETHEMA registry includes all suspected APL patients regardless of treatment or diagnosis, investigators may include preferably those cases evaluable for PML-RARα therapeutic protocols; (2) a number of registered APL patients were excluded from this study because of lack of genetic diagnosis.